Resilience is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. They are focused on creating processes and platforms to enable scientists to make novel therapies quickly, safely, and at scale.

Resilience

Ology Bioservices, Inc.

Therapure Biopharma Inc

Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. 

U.S. Department of Defense

U.S. International Development Finance Corp

Mubadala

Magnetic Ventures

ARCH Venture Partners

Google Ventures

Lux Capital

New Enterprise Associates

When your need for larger-scale vaccine production outgrows your cell stacks or flasks, there is a clear and easy path to scale up and maximize your yields. 

Learn how our team of process development experts and proprietary Vero and Quail cell lines can support the development of your vaccine with Path-to-PAD (Process and Analytical Development) in our latest blog post: https://hubs.ly/Q02l0J9Q0 

#Development #Vaccine #CellLine

On #RareDiseaseDay, Resilience joins the rare disease community in advocating for people and families living with rare diseases. 
 
We are honored to partner with @BridgeBio, as together we remain dedicated to accelerating the development of innovative therapies for families living with Canavan disease and congenital adrenal hyperplasia.
 
Learn more:https://hubs.ly/Q02m7gP00

Drug Development & Delivery recently interviewed Resilience Chief Commercial Officer Syed T. Husain about how Resilience was built to revolutionize the CDMO space with a refocus on the foundations of biomanufacturing, a reprioritization on manufacturing technology development, and a redefinition of partnership. Read the full article: https://hubs.ly/Q02kTsdy0 

DCAT Week 2024 is just around the corner – make the most of your time in New York City by securing a meeting with Resilience. Request a meeting: https://hubs.ly/Q02m5z6x0 

#DCATWeek


The need for advanced technology platforms that offer a clear, end-to-end path to commercial manufacturing is driving biotech companies to outsource critical stages of their biomanufacturing processes.

Our recent whitepaper, "The Stage-Gate Model: A Value-Driven Approach to Accelerate Biomanufacturing," highlights how to perform critical activities leveraging process and analytical development resources from early-stage clinical to commercialization: https://hubs.ly/Q02hyVMH0

#biomanufacturing #techtransfer #processdevelopment #analyticaldevelopment #resilience

msh id	COM:RESILIENCE
symbol	-
name	Resilience
homepage url	https://resilience.com
country	US
sector	Healthcare & Health Services
industry	Biotechnology Research
market	PRIVATE
employee count	1.67K
crunchbase url	https://www.crunchbase.com/organization/resilience-e701
linkedin url	https://www.linkedin.com/company/weareresilience
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:RESILIENCE

Resilience

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-